Upregulated expression of LOX is a novel independent prognostic marker of worse outcome in gastric cancer patients after curative surgery

QING ZHANG1, XIAO-SHUN JIN1, ZHONG-YIN YANG1, MIN WEI1, XIAO-CHENG ZHU2, PING WANG3, BING-YA LIU1 and QIN-LONG GU1

1Department of General Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025; 2Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou 221002; 3Department of Pathology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China

Received August 28, 2012; Accepted November 26, 2012

DOI: 10.3892/ol.2012.1092

Abstract. Lysyl oxidase (LOX) initiates the enzymatic stage of collagen and elastin cross-linking. It also has intracellular functions involved in the regulation of cell differentiation, motility/migration and gene transcription. Aberrant expression of the LOX gene has been reported in multiple tumors. However, the correlation of its expression with clinicopathological parameters and its prognostic significance in gastric cancer remains largely unknown. In order to address this problem, total RNA of paired tissue samples (n=10) and a tissue microarray containing 161 paired tissues from patients with gastric cancers at different stages were collected. Quantitative real-time PCR and immunochemistry assay were conducted to investigate the expression of LOX. Based on the results, LOX mRNA was increased in gastric cancer tissues compared with the adjacent normal mucosa. Immunohistochemical detection revealed that expression of LOX was associated with depth of tumor invasion (P<0.05), lymph node status (P<0.05), TNM stage (P<0.05) and survival (P<0.05). Cox regression analysis revealed that positive expression of LOX (P=0.026) was an independent prognostic marker for survival in patients with gastric cancer.

Introduction

The lysyl oxidase (LOX) gene family comprises five members which act as extracellular modulating enzymes; LOX, LOXL1, LOXL2, LOXL3 and LOXL4 (1). The first identified and the more studied member of this family is LOX. The human LOX gene which spans across 15 kb of genomic DNA is located on chromosome 5 (5q23.3-31.2) and is comprised of seven exons that encode a 417-amino acid protein. LOX is synthesized as a 48-kDa preproprotein (preproLOX) which includes a 21-amino acid signal sequence at the amino terminus (2,3). PreproLOX is N-glycosylated and secreted from the cell as a catalytically inactive 50-kDa proenzyme protein (proLOX). ProLOX is subsequently cleaved into a catalytically mature 32-kDa protein (LOX) and a 180-kDa LOX-PP (1). The amino terminus of LOX contains the most unique sequence, while the carboxy terminus is highly conserved among its family members and is responsible for catalytic activity. The carboxy terminus contains a copper-binding site, lysyl tyrosyl quinine cofactor binding residues, a catalytically active site, a cytokine receptor and growth factor receptor-like domain (2,3).

LOX is a copper-dependent amine oxidase that maintains the covalent cross-linking of collagens and elastin in extracellular matrices, which is essential for normal function of connective tissue, embryonic development and adult tissue remodeling (4). Aberrant LOX expression or enzymatic activity is correlated with certain diseases, including cutis laxa, Menkes' syndrome, spontaneous coronary artery dissection (5-7), atherosclerosis, scleroderma, liver cirrhosis and senile plaque formation in Alzheimer's and non-Alzheimer's dementia (8-10).

Recent studies have demonstrated that LOX has intracellular functions involved in the regulation of cell differentiation, motility/migration, gene transcription and cell adhesion. The aberrant LOX expression and activity that have been observed in various cancerous tissues and neoplastic cell lines are of interest (11). The role of LOX in cancer has been controversial, due to both down- and upregulation of LOX in tumor tissues and cancer cell lines, which have been found in initial studies, suggesting a dual role for LOX as a tumor suppressor, as well as a metastasis-promoting gene (11-13).

Gastric cancer is one of the most common types of tumors and remains the second leading cause of cancer mortality in...
the world although the diagnosis and treatment of such patients have improved (14). Surgical resection is the main treatment modality and is able to cure patients with early-stage cancer. However, the survival rate of patients with advanced resectable gastric cancer remains poor, despite new treatment strategies, such as perioperative chemotherapy (15) and adjuvant chemoradiation (16).

Currently, numerous gastric cancer patients are diagnosed when the tumor is at an unresectable stage. For these patients, systemic chemotherapy is the main treatment option as it is able to prolong survival without impacting on quality of life. Certain single agents and combinations are effective in the treatment of such metastatic disease, but the survival of patients with advanced gastric cancer treated with palliative chemotherapy remains low. New therapies are therefore urgently needed.

At present, the TNM stage, tumor differentiation and histological classification are the primary criteria for predicting the clinical outcome in gastric cancer. As a highly heterogeneous tumor, prognosis in gastric cancer, however, often varies among patients with the same clinicopathological parameters in practice. Therefore, additional classification parameters need to be defined in addition to the TNM and the classic pathological characteristics of the tumor in order to better identify the biological subsets of this disease. Biological prognostic factors are often derived from the genetic process, which is thought to represent a crucial step to gastric cancer. Some of these potential prognostic factors may also be predictive of response to therapy as they are a molecular target either to chemotherapeutics or to biological/targeted therapies (17). With the aid of microarray technology, the identification of LOX as a potential modulator of tumorigenesis and/or metastatic tumor progression was carried out in this study.

Materials and methods

Patients and tissue samples. This study was approved by the Research Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China. Written informed consent was obtained from all the patients enrolled in this study. All specimens were handled and made anonymous according to the ethical and legal standards.

Tissue specimens for real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). Fresh specimens for qRT-PCR were obtained from 10 patients who underwent surgery for gastric cancer between March and May 2010 at the Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Grossly visible normal and cancerous portions of the specimens were snap-frozen in liquid nitrogen and stored at -85°C. None of the patients had received radiotherapy or chemotherapy prior to surgery.

Tissue specimens and microarray construction. A total of 161 patients who had undergone curative surgery for gastric cancer at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, between January 2002 and December 2003 were enrolled in the study. Patient-derived specimens were collected and archived under protocols approved by the Institutional Review Boards of Shanghai Jiao Tong University. The group was composed of 107 males and 54 females with a mean age of 57 (range, 28-80) years at the time of surgery. There were 63 cases at stage I, 39 at stage II, 46 at stage III and 13 at stage IV. The diagnoses were confirmed by two pathologists, and the tumor grade and stage classifications were assigned according to the International Union Against Cancer guidelines (18). None of the patients had received radiotherapy or chemotherapy prior to surgery. Patients with advanced gastric cancer received standard chemotherapeutic protocols, including 5-fluorouracil postoperatively, according to the NCCN Practice Guidelines for Gastric Cancer (19). All patients were subjected to close follow-up observation. The follow-up deadline was October 2010.

For tissue microarray (TMA) construction, formalin-fixed, paraffin-embedded samples obtained from the above 161 patients that contained primary tumors and adjacent normal mucosa were retrieved from the archives of the Department of Pathology in Ruijin Hospital. Hematoxylin and eosin (H&E)-stained slides were screened for tumor tissue and non-cancerous tissue adjacent to the tumor (≥2 cm from the tumor). Representative areas of tissue were established and 2.0-mm diameter cores were punched from the paraffin blocks. Two cores from each tumor and paired normal tissue (≥2 cm from the tumor) were arrayed next to each other to ensure similar reaction conditions. All specimens were examined by two pathologists to prevent bias. Tumor and normal mucosa morphology on the arrays were validated as having high accordance with the whole archived section. TMA slides were constructed and made in collaboration with Shanghai Biochip (Shanghai, China).

Real-time qPCR. Total RNA in 10 paired, frozen primary gastric cancer tissues and adjacent normal mucosa were extracted according to the manufacturer’s instructions (Life Technologies, Carlsbad, CA, USA), and then 0.5 µg RNA was reverse transcribed into cDNA using a PrimerScript™ RT reagent kit (Takara Bio Inc., Dalian, China). qPCR was performed in a 10-ml total reaction mixture. Quantitative LOX mRNA levels were assessed using ABI 7500 real-time PCR System (Applied Biosystems, Carlsbad, CA, USA) with a Master Mix kit (Takara Bio Inc.) according to the manufacturer’s instructions. GAPDH was used as an internal control. Each real-time PCR was repeated 3 times and the 2^(-ΔΔCT) method was used for normalization with GAPDH as a reference gene. Gene expression with a ratio of >2 was considered to be upregulated. The sequences for qRT-PCR primers were as follows: GAPDH forward, 5'-TGTGGCATCAATGACCCCTT-3'; GAPDH reverse, 5'-CTCCACGACGTACTCCGG-3'; LOX forward, 5'-CACAGGGACATCATGCATGGTATGC-3'; LOX reverse, 5'-CCACTTTCAGAACACAGGCGAC-3'.

Immunohistochemistry. The TMA sections were deparaffinized in xylene and rehydrated in graded series of ethanolos followed by heat-induced epitope retrieval in citrate buffer (pH 6.0). LOX expression was detected using a primary antibody against LOX (anti-LOX antibody, rabbit polyclonal to LOX, 1/300; Abcam, Cambridge, MA, USA). After incubation with a biotinylated secondary antibody and DAB (Dako, Carpinteria, CA, USA), the slides were rinsed and
counterstained with Mayer's hematoxylin. Staining was scored by two independent investigators without knowledge of patient outcomes according to the staining intensity and extent as described previously (20). To evaluate LOX expression, immuno-staining was classified into four groups according to both intensity and extent. The proportion of cell protein expression was categorized as follows: 0, 0% immunopositive cells; 1, <10% positive cells; 2, 11-50% positive cells; 3, 51-75% positive cells; and 4, >75% positive cells. The staining intensity was categorized by relative intensity as follows: 0, negative; 1, weak; 3, moderate; 4, strong. The proportion and intensity scores were then multiplied to obtain a total score. To obtain final statistical results, scores ≤2 were considered as negative, while scores of 3-4 were considered as (+), scores of 5-8 as (++) and scores of 9-16 as (+++).

Statistical analysis. Statistical analysis was performed using SPSS 17.0 statistical software (Chicago, IL, USA). Correlation was assessed with the Spearman Rho correlation coefficient and Pearson Chi-square test. Kaplan-Meier survival curves were generated and survival data were analyzed with the log-rank test and Cox proportional hazards regression. P<0.05 was considered to indicate a statistically significant result.

Results

Upregulation of LOX expression in primary gastric cancer tissues compared with adjacent normal mucosa. Of the 10 paired cases used for the evaluation of LOX mRNA and protein expression, 7 (70%) gastric cancer tissues showed at least a four-fold increase in LOX mRNA level compared with the adjacent non-cancerous mucosa. The difference in LOX mRNA expression was significant (70 vs 30%; P<0.05; Fig. 1).

Association of LOX TMA immunohistochemical staining with patient clinicopathological parameters. The expression of LOX was predominantly localized in the cytoplasm and nuclei of tumor cells. Of the 161 TMA specimens, expression of LOX was observed in 68 (42.2%) of the tumors. Of these, 54 cases had a score of +, 6 cases had a score of ++ and 8 cases had a score of ++++. Meanwhile 20 (12.4%) of the adjacent noncancerous mucosa displayed positive staining. The difference in LOX expression between tumor cells and adjacent noncancerous mucosa was significant (42.2 vs 12.4%, P<0.05; Fig. 2). Associations between clinicopathological factors and LOX expression are summarized in Table I. Increased LOX expression was significantly correlated with the depth of tumor invasion, lymph node status and TNM stage (P<0.05; Table I).

Survival analysis and prognostic significance of LOX expression. Kaplan-Meier curves showed that patients with positive LOX expression had a lower overall survival rate than the
group with negative LOX expression (P<0.05; Fig. 3). As expected, the established clinical parameters of the tumor size, lymph node status, depth of tumor invasion and TNM stage significantly affected survival (P<0.05; Fig. 4).

In the Cox multiple regression analysis, depth of tumor invasion, histological differentiation, lymph node status and LOX expression independently significantly affected survival (Table II).
Currently, the TNM stage is the most frequently used for predicting prognosis for gastric cancer. This classification system takes into account the depth of invasion of gastric wall (T), the involvement of lymph nodes (N) and the presence of distant metastasis (M). In the present study, the results of univariate analysis showed that tumor size, depth of invasion, involvement of lymph nodes and TNM stage are associated with the prognosis in gastric cancer, which was consistent with the results of previous studies (18).

LOX was initially reported as a copper-dependent amine oxidase responsible for the catalysis of collagen and elastin cross-linking within the extracellular matrix. However, previous studies have shown that LOX may have intracellular functions, including the regulation of cell differentiation, motility/migration and gene transcription (11,21). Since LOX protein structure and function are so complex and involve vital biological processes, such as cell movement, signal transduction and gene regulation, it is evident that aberrant regulation of LOX may lead to tumorigenesis and tumor progression (11).

Neoplastic transformation occurs as a result of genetic and epigenetic alterations in signalling pathways that mediate cell growth, cell cycle arrest and apoptosis. Genetic alterations may occur through mutational activation (e.g., oncogenes), mutational inactivation and loss of heterozygosity (e.g., tumor suppressor genes), as well as epigenetically (e.g., methylation/demethylation of CpG dinucleotides) (22). A decrease in LOX mRNA and/or protein has been observed in basal and squamous cell, bronchogenic, colon, esophageal, gastric, head and neck squamous cell, pancreatic and prostatic carcinomas, as well as melanoma (11). The lack of LOX protein in tumor cells originating from keratinocytes is clearly associated with human basal cell carcinoma and squamous cell carcinoma skin cancers. The inhibition of the LOX enzymatic activity in the skin equivalent model induces basement membrane disruption and deregulation of filaggrin and K10 expression of the dermis, preparing a phenotype favorable to tumor devel-

Figure 3. Univariate analysis of LOX protein expression with reference to overall survival (P<0.05). Survival curve of patients with gastric cancer with regard to LOX expression. Patients with positive LOX expression had a lower overall survival rate than patients with negative expression (P<0.05). LOX, lysyl oxidase.

**Discussion**

Figure 4. Univariate analysis of (A) tumor diameter (P<0.001), (B) depth of tumor invasion (P<0.001), (C) lymph node status (P<0.001) and (D) TNM stage (P<0.05) with reference to survival.
The loss of LOX protein adds another step towards invasion (23). As for the role of LOX in gastric cancer, Kaneda et al (12) found that loss of heterozygosity and promoter methylation of LOX were detected in 33% (9 of 27) and 27% (26 of 96) of gastric cancers, respectively, suggesting that LOX is a tumor suppressor gene inactivated by methylation in human gastric cancers. Methylation-associated silencing of LOH was also observed in lung, colon and ovarian cancer cell lines (11). However, in our study, upregulated expression of LOX mRNA and protein has been found in gastric cancer. This finding suggests that there may be another mechanism by which LOX is involved in gastric cancer progression.

Tumor cell invasion is a complex process that involves attachment to, degradation of and detachment from an extracellular matrix, and finally active migration away from the primary tumor (10). Similar to tumorigenesis, metastatic progression also emerges as a result of genetic and epigenetic alterations in pathways that mediate cell invasion, survival outside of the primary tumor microenvironment and colonization/growth at a distant organ site (24). Tumor metastasis may be influenced by both the immediate microenvironment (cell-cell or cell-matrix interactions) and the extended tumor microenvironment.

An increase in LOX mRNA and/or protein has also been observed in breast (25), head and neck squamous cell (25), prostatic (26) and clear cell renal cell carcinoma (27), compared with their normal or non-aggressive neoplastic counterparts. In these studies, the expression of high levels of LOX mRNA and/or protein was a poor prognostic factor and was associated with poorly differentiated, high-grade tumors, increased recurrence rates and decreased overall survival. In our study, we also found that LOX protein expression was significantly correlated with depth of tumor invasion, lymph node status, and TNM stage. Upregulated expression of LOX was an independent prognostic marker of a worse outcome in gastric cancer patients. The strong correlations suggested that LOX upregulation may promote tumor invasion and metastasis and that LOX may possibly be used as a biomarker to identify subsets of gastric cancer with a more aggressive phenotype. These preliminary findings need to be verified in a larger, prospective, controlled, clinical study. The mechanism by which LOX is involved in gastric cancer progression has not been well elucidated in this study.

Acknowledgements

This study was supported by grants from National Natural Science Foundation of China (Nos. 81172324 and 30900670), Science and Technology Commission of Shanghai Municipality (Nos. 10jc141100, 09DZ1950100 and 09DZ2260200), Shanghai Key Discipline (S30204) and Key Projects in the National Science & Technology Pillar Program of China (Nos. 2008BA152B03 and 2011BA203191).

References

1. Panchenko MV, Stettler-Stevenson WG, Trubetskoy OV, Gacheru SN and Kagan HM: Metalloproteinase activity secreted by heterogenic cells in the processing of prolysyl oxidase: Potential role of procollagen C-proteinase. J Biol Chem 271: 7113-7119, 1996.
2. Cissis K: Lysyl oxidases: A novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol 70: 1-32, 2001.
3. Lucero HA and Kagan HM: Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci 63: 2304-2316, 2006.
4. Pinnell SR and Martin GR: The cross-linking of collagen and elastin: enzymatic conversion of lysine in peptide linkage to alpha-aminoadipic-delta-semialdehyde (allysine) by an extract from bone. Proc Natl Acad Sci USA 61: 708-710, 1968.
5. Khakoo A, Thomas R, Trompeter R, Duffy P, Price R and Pope FM: Congenital cutis laxa and lysyl oxidase deficiency. Clin Genet 51: 109-114, 1997.
6. Royce PM, Camakaris J and Danks DM: Reduced lysyl oxidase activity in skin fibroblasts from patients with Menkes's syndrome. Biochem J 192: 579-586, 1980.
7. Sibon I, Sommer P, Lamaziere JM and Bonnet J: Lysyl oxidase deficiency: a new cause of human arterial desiccation. Heart 91: e33, 2005.
8. Kagan HM, Raghavan J and Hollander W: Changes in aortic lysyl oxidase activity in diet-induced atherosclerosis in the rabbit. Arteriosclerosis 1: 287-291, 1981.
9. Kagan HM: Lysyl oxidase: mechanism, regulation and relationship to liver fibrosis. Pathol Res Pract 190: 910-919, 1994.
10. Gilad GM, Kagan HM and Gilad VH: Evidence for increased lysyl oxidase, the extracellular matrix-forming enzyme, in Alzheimer's disease brain. Neurosci Lett 376: 210-214, 2005.
11. Payne SL, Hendrix MJ and Kirschmann DA: Paradoxical roles for lysyl oxidases in cancer - a prospect. Cell Biochem 101: 1338-1354, 2007.
12. Kaneda A, Wakazono K, Tsukamoto T, et al: Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res 64: 6410-6415, 2004.
13. Payne SL, Fogelgren B, Hess AR, et al: Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res 65: 11429-11436, 2005.
14. Kelley JR and Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56: 1-9, 2003.
15. Cunningham D, Allum WH, Stenning SP, et al; MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Eng J Med 355: 11-20, 2006.
16. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Eng J Med 345: 725-730, 2001.
17. Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R and Cascinu S: Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 30: 451-459, 2004.

18. Sobin LH and Wittekind C: TNM Classification of Malignant Tumors. 6th edition. Wiley-Liss, New York, 2002.

19. Ajani J, D'Amico TA, Hayman JA, Meropol NJ and Minsky B; National Comprehensive Cancer Network. Gastric cancer: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 1: 28-39, 2003.

20. Xu C, Zheng P, Shen S, et al: NMR structure and regulated expression in APL cell of human SH3BGRL3. FEBS Lett 579: 2788-2794, 2005.

21. Kagan HM and Li W: Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 88: 660-672, 2003.

22. Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med 10: 789-799, 2004.

23. Bouez C, Reynaud C, Noblesse E, et al: The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. Clin Cancer Res 12: 1463-1469, 2006.

24. Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12: 895-903, 2006.

25. Erler JT, Bennewith KL, Nicolau M, et al: Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222-1226, 2006.

26. Lapointe J, Li C, Higgins JP, et al: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811-816, 2004.

27. Stassar MJ, Devitt G, Brosius M, et al: Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer 85: 1372-1382, 2001.

28. Wilgus ML, Borczuk AC, Stoopler M, Ginsburg M, Gorenstein L, Sonett JR and Powell CA: Lysyl oxidase: a lung adenocarcinoma biomarker of invasion and survival. Cancer 117: 2186-2191, 2011.

29. Li W, Nellaiappan K, Strassmaier T, Graham L, Thomas KM and Kagan HM: Localization and activity of lysyl oxidase within nuclei of fibrogenic cells. Proc Natl Acad Sci USA 94: 12817-12822, 1997.